Table 1 EOC patient cases and respective PDCs included in the study.

From: Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma

Patient ID

Histological OC subtype

Disease stage

Sample type

Key oncogenic aberrations

Selected drug efficacies seen in PDCs

FMOC04

HGSOC

Recurrent

(peritoneal metastases)

Ascites

TP53 p.R175H, CCNE1 Amp, MECOM Amp, PIK3CA gain

AZD1775 (Wee1i), prexasertib (Chki)

FMOC09

HGSOC

Primary

Tissue

TP53 p.R283P, CCNE1 Amp, MECOM Amp, PIK3CA Amp, FNBP4-PTPMT1 fusion

Anagrelide (PDE-3i), dasatinib (multikinasei), afatinib (ERBB2/EGFRi), prexasertib (Chki)

FMOC11

HGSOC

Primary

Tissue

TP53 frameshift, MYC Amp, KRAS Amp, PIK3CA gain, ING5-THAP4 fusion, ROCK1-SS18 fusion

AZD1775 (Wee1i), prexasertib (Chki), poziotinib (pan-ERBBi), dasatinib (multikinasei)

FMOC14

HGSOC

Peritoneal metastases

Ascites

TP53 p.A161T, broad CNV changes incl. PIK3CA gain

AZD1775 (Wee1i), prexasertib (Chki), omipalisib (PI3K/mTORi), AZD8055 (mTORi)

FMOC24

HGSOC

Primary, progressive

Ascites

TP53 p.R273C, CCNE1 and KRAS Amp, PIK3CA gain, RCC1-UBE2D2 fusion

NVP-LCL161 & birinapant (SMAC mimetic), prexaserib (Chki), navitoclax (BCL-2i)

FMOC02

(FMOC02_1

FMOC02_2

FMOC02_3)

LGSOC

Recurrent

(peritoneal metastases)

(1) Ascites (FMOC02_1)

(2) Needle biopsy (FMOC02_2)

(3) Ascites (FMOC02_3)

TP53 wt, CLU-NRG1 fusion,

CDKN2A homozygous loss

Poziotinib & dacomitinib (pan-ERBBi), afatinib (ERBB2/EGFRi), AZD8055 (mTORi), SCH772984 (ERK1/2i), AMG-232 (MDM2i)

FMOC17

LGSOC

Primary

Tissue

TP53 wt, CDKN2A homozygous loss

Poziotinib (pan-ERBBi), dasatinib (multikinasei), SCH772984 (ERK1/2i), AMG-232 (MDM2i)

FMOC25

(FMOC25_1

FMOC25_2)

LGSOC

Primary, progressive

(1) Tissue (FMOC25_1)

(2) Tissue (FMOC25_2)

TP53 wt, TACSTD2-OMA1 fusion, CDKN2A homozygous loss (FMOC25_2)

AZD8055 (mTORi), NVP-BGT226 & omipalisib (PI3K/mTORi), SCH772984 (ERK1/2i), AMG-232 (MDM2i)

FMOC27

LGSOC

Primary

Tissue

TP53 wt, CDKN2A homozygous loss

Poziotinib & dacomitinib (pan-ERBBi), afatinib (ERBB2/EGFRi), SCH772984 (ERK1/2i), AMG-232 (MDM2i)

FMOC28

LGSOC

Primary

Tissue

TP53 wt, CDKN2A homozygous loss

AZD8055 (mTORi), poziotinib (pan-ERBBi), NVP-BGT226 (PI3K/mTORi), AMG-232 (MDM2i)

FMOC03

MUCOC

Primary

Tissue

TP53 p.G244V, WT1 p.H469Y, ERBB2 Amp.

Poziotinib (pan-ERBBi), SCH772984 (ERK1/2i), afatinib (ERBB2/EGFRi)

FMOC06

MUCOC

Recurrent

Ascites

TP53 p.S215N, KRAS p.G12D,

CDKN2A & MTAP homozygous loss

Omipalisib (PI3K/mTORi), AZD8055 (mTORi), SCH772984 (ERK1/2i), selumetinib & trametinib (MEKi)

FMOC22

MUCOC

Primary

Ascites

TP53 p.D281H, KRAS p.G12V, CDKN2A & MTAP homozygous loss

Prexasertib (Chki), AZD8055 (mTORi), SCH772984 (ERK1/2i)

  1. In addition to histological EOC subtype and disease stage, the key oncogenic aberrations are presented for each patient case along with the selective effective targeted drugs based on the DSRT platform. More detailed clinical characteristics for patient cases are presented in the Supplementary Table S1A. HGSOC high-grade serous ovarian carcinoma, LGSOC low-grade serous ovarian carcinoma, MUCOC mucinous ovarian cancer.
Back to article page